TY - JOUR
T1 - Prognostic Impact of C-Reactive Protein-to-Lymphocyte Ratio in Non-small Cell Lung Cancer
T2 - A Propensity Score-Matching Analysis
AU - Nagano, Taichi
AU - Kinoshita, Fumihiko
AU - Hashinokuchi, Asato
AU - Matsudo, Kyoto
AU - Watanabe, Kenji
AU - Takamori, Shinkichi
AU - Kohno, Mikihiro
AU - Miura, Naoko
AU - Shimokawa, Mototsugu
AU - Takenaka, Tomoyoshi
AU - Yoshizumi, Tomoharu
N1 - Funding Information:
The authors thank Sarah Ivins, PhD, and H. Nikki March, PhD, from Edanz (https://jp.edanz.com/ac ) for editing a draft of this manuscript.
Publisher Copyright:
© 2023, Society of Surgical Oncology.
PY - 2023/6
Y1 - 2023/6
N2 - Background: Many inflammatory and nutritional markers have been used to predict prognosis in lung cancer. The C-reactive protein (CRP)-to-lymphocyte ratio (CLR) is a useful prognostic factor in various cancers. However, the prognostic value of preoperative CLR in patients with non-small cell lung cancer (NSCLC) remains to be established. We examined the significance of the CLR compared with known markers. Methods: A total of 1380 surgically resected NSCLC patients treated at two centers were recruited and divided into derivation and validation cohorts. After CLRs were calculated, patients were classified into high and low CLR groups based on the cutoff value determined by receiver operating characteristics curve analysis. Subsequently, we determined the statistical associations of the CLR with clinicopathological factors and prognosis and further analyzed its prognostic impact by propensity-score matching. Results: Of all the inflammatory markers examined, CLR yielded the highest area-under-the-curve value. The prognostic impact of CLR remained significant after propensity-score matching. Prognosis was significantly worse in the high-CLR group than in the low-CLR group (5-year, disease-free survival [DFS]: 58.1% vs. 81.9%, P < 0.001; 5-year overall survival [OS]: 72.1% vs. 91.2%, P < 0.001). The results were confirmed in the validation cohorts. Multivariable analysis also showed high CLR as an independent factor for both DFS and OS (DFS: hazard ratio [HR] 1.42, P = 0.027; OS: HR 1.95, P = 0.0037). Conclusions: Preoperative CLR is a useful marker for predicting the prognosis of NSCLC patients who have undergone surgery.
AB - Background: Many inflammatory and nutritional markers have been used to predict prognosis in lung cancer. The C-reactive protein (CRP)-to-lymphocyte ratio (CLR) is a useful prognostic factor in various cancers. However, the prognostic value of preoperative CLR in patients with non-small cell lung cancer (NSCLC) remains to be established. We examined the significance of the CLR compared with known markers. Methods: A total of 1380 surgically resected NSCLC patients treated at two centers were recruited and divided into derivation and validation cohorts. After CLRs were calculated, patients were classified into high and low CLR groups based on the cutoff value determined by receiver operating characteristics curve analysis. Subsequently, we determined the statistical associations of the CLR with clinicopathological factors and prognosis and further analyzed its prognostic impact by propensity-score matching. Results: Of all the inflammatory markers examined, CLR yielded the highest area-under-the-curve value. The prognostic impact of CLR remained significant after propensity-score matching. Prognosis was significantly worse in the high-CLR group than in the low-CLR group (5-year, disease-free survival [DFS]: 58.1% vs. 81.9%, P < 0.001; 5-year overall survival [OS]: 72.1% vs. 91.2%, P < 0.001). The results were confirmed in the validation cohorts. Multivariable analysis also showed high CLR as an independent factor for both DFS and OS (DFS: hazard ratio [HR] 1.42, P = 0.027; OS: HR 1.95, P = 0.0037). Conclusions: Preoperative CLR is a useful marker for predicting the prognosis of NSCLC patients who have undergone surgery.
UR - http://www.scopus.com/inward/record.url?scp=85148937009&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85148937009&partnerID=8YFLogxK
U2 - 10.1245/s10434-023-13250-8
DO - 10.1245/s10434-023-13250-8
M3 - Article
C2 - 36847957
AN - SCOPUS:85148937009
SN - 1068-9265
VL - 30
SP - 3781
EP - 3788
JO - Annals of Surgical Oncology
JF - Annals of Surgical Oncology
IS - 6
ER -